CHICAGO TRUST Co NA Has $2.32 Million Stock Holdings in DexCom, Inc. $DXCM

CHICAGO TRUST Co NA boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 446.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 36,906 shares of the medical device company’s stock after purchasing an additional 30,150 shares during the quarter. CHICAGO TRUST Co NA’s holdings in DexCom were worth $2,318,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the business. Trust Co. of Vermont lifted its holdings in shares of DexCom by 14.8% during the fourth quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock worth $74,000 after buying an additional 145 shares during the last quarter. CVA Family Office LLC grew its stake in shares of DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after acquiring an additional 147 shares during the last quarter. IFP Advisors Inc increased its position in DexCom by 24.7% during the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after acquiring an additional 178 shares during the period. Keel Point LLC increased its position in DexCom by 3.1% during the fourth quarter. Keel Point LLC now owns 6,473 shares of the medical device company’s stock worth $430,000 after acquiring an additional 193 shares during the period. Finally, Integrated Wealth Concepts LLC raised its stake in DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after purchasing an additional 196 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Insider Activity

In other DexCom news, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total transaction of $60,730.12. Following the sale, the director directly owned 25,007 shares of the company’s stock, valued at approximately $1,500,670.07. The trade was a 3.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the sale, the executive vice president owned 106,353 shares in the company, valued at approximately $8,034,969.15. This represents a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 46,694 shares of company stock valued at $3,343,977. 0.28% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on DXCM. Sanford C. Bernstein set a $77.00 price target on shares of DexCom in a report on Friday, May 1st. Raymond James Financial restated a “strong-buy” rating and set a $91.00 price objective on shares of DexCom in a report on Monday, June 8th. TD Cowen reaffirmed a “buy” rating and issued a $95.00 price target (up from $75.00) on shares of DexCom in a report on Wednesday, June 10th. Bank of America decreased their price objective on DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Finally, Wall Street Zen cut DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $84.88.

DexCom Price Performance

NASDAQ:DXCM opened at $68.86 on Thursday. The company has a 50-day moving average of $67.98 and a 200-day moving average of $68.12. The company has a market capitalization of $26.57 billion, a price-to-earnings ratio of 29.43, a PEG ratio of 1.11 and a beta of 1.45. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm’s revenue was up 15.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.32 EPS. As a group, equities research analysts anticipate that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.